Occupational Activity

ESMO Spotlight: Flagship ADCs move into early-stage cancer to validate chemo-displacement ambitions

1 week ago talkbio0Tagged 2025, ADCs, Administration occupational activities, Antibody-Drug Conjugates, Biological Markers, chemo-displacement, Datopotamab deruxtecan, Datroway, Enhertu, ESMO, HER2-positive, Limited stage (cancer stage), Malignant neoplasm of breast, Toxicity aspects, trastuzumab, Triple Negative Breast Neoplasms

ESMO 2025; antibody-drug conjugates; ADCs; early-stage cancer; chemo-displacement; trastuzumab deruxtecan; ENHERTU; datopotamab deruxtecan; DATROWAY; breast cancer; HER2-positive; triple-negative breast cancer; biomarkers; toxicity management

Accuray Accelerates Transformation Efforts with Appointments of Experienced Executive Leaders

1 week ago talkbio0Tagged Accuray, cell transformation, CEO, Change, Organizational, executive appointments, Leadership, med-tech, operational transformation, Steve La Neve, Suzanne Winter, Transition Mutation

Accuray; transformation; executive appointments; Steve La Neve; CEO; Suzanne Winter; organizational change; operational transformation; med-tech; leadership transition

Weight-loss drug stocks drop after Trump pledges major price cuts

1 week ago talkbio0Tagged Administration occupational activities, Drops - Drug Form, drug price, eli lilly, Glucagon-Like Peptide 1, Nordisk, Ozempic, Wegovy, Weight-Loss Agents

weight-loss drugs; ozempic; wegovy; novo nordisk; eli lilly; stock drop; drug pricing; trump administration; GLP-1

Are the Good Times in Biotech Back? – Insights from Post-Hoc Live’s 2025 Industry Sentiment

2 weeks ago talkbio0Tagged Aggressive Periodontitis, delays, executive survey, Funding, Industry, M&A, Post-Hoc Live, public biotech, Sentiment, United States Food and Drug Administration

biotech sentiment; Post-Hoc Live; 2025 industry outlook; biotech M&A; FDA delays; executive survey; public biotech companies; JP Morgan effect; biotech funding

UK Proposes Raising Payment Scheme for Branded Medicines to Nearly 25% Amid Industry Pushback

3 weeks ago talkbio0Tagged Consultation, drugmakers, Industry, Nance-Horan syndrome, payment, pharmaceutical rebates, Pricing, Response process, spending, statutory scheme, UK

UK medicine pricing; NHS spending; statutory scheme; drugmakers; payment percentage; pharmaceutical rebates; industry response; consultation 2025

The 5 Most Powerful Women in Biopharma: 2025 News & Key Figures

3 weeks ago talkbio0Tagged Belén, Biopharma, CEO, Garijo, Leadership, Reshma Kewalramani, Sarah Boyce, Woman, Women, Yvonne Greenstreet

powerful women; biopharma; female CEO; Reshma Kewalramani; Yvonne Greenstreet; Sarah Boyce; Emma Walmsley; Belén Garijo; leadership

Endpoints News Launches Industry Sentiment Survey, But No Evidence Yet of a New Biopharma Sentiment Index

3 weeks ago talkbio0Tagged Biopharma, Endpoints, Industry, John Carroll, News [Publication Type], Sentiment, Surveys, trends qualifier

Endpoints News; biopharma; sentiment; survey; industry trends; John Carroll

Meeting on the Mesa 2025 Arrives Amid Mixed Signals for Cell and Gene Therapy Sector

3 weeks ago talkbio0Tagged Advanced therapies, Alternative, Cells, Clinical Trials, commercialization, Gene Modification, gene therapy, Industry, meeting, MESA, partnerships, payment, Phoenix Arizona, regulatory challenges, RNA, Messenger, Study models

Cell and gene therapy; Meeting on the Mesa; Commercialization; Clinical trials; Advanced therapies; Industry partnerships; Regulatory challenges; Phoenix Arizona; mRNA; Gene editing; Alternative payment models

Legal Pressure Escalates as FDA Intensifies Crackdown on Direct-to-Consumer Pharma Advertising

4 weeks ago talkbio0Tagged Advertising (activity), CHARGE Syndrome, Compound, Direct-to-Consumer Advertising, enforcement, Legal Challenges, pharmaceutical advertising crackdown, Pharmacy facility, prescription drug ads, Preventive monitoring, United States Food and Drug Administration, warning letters

FDA enforcement; direct-to-consumer advertising; pharmaceutical advertising crackdown; warning letters; legal challenges; AI monitoring; prescription drug ads; transparency in advertising; HHS; compounding pharmacies

Vaxcyte Strikes up to $1B Fill-Finish Manufacturing Deal with Thermo Fisher at North Carolina Facility

4 weeks ago talkbio0Tagged biomanufacturing, commercial supply chain, Manufacturing, North Carolina, PCVs, pneumococcal conjugate vaccines, production, Thermo Fisher Scientific, United States, Vaccines, VAX-24, VAX-31, Vaxcyte

Vaxcyte; Thermo Fisher Scientific; fill-finish manufacturing; North Carolina; pneumococcal conjugate vaccines; PCVs; VAX-31; VAX-24; commercial supply chain; biomanufacturing; U.S. vaccine production; $1 billion deal